New technique predicts gene resistance to cancer treatments

Yale School of Public Health researchers have developed a new method to predict likely resistance paths to cancer therapeutics, and a methodology to apply it to one of the most frequent cancer-causing genes. That gene, KRAS, is mutated in approximately 20 percent of all human cancers and has a major presence in pancreatic, colorectal and lung cancers, can continue to mutate and evolve even after successful chemotherapy, radiotherapy or drug treatment.